Kumar S, Harrison S, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 24th Congress of EHA, abstract LB2601.
Epcoritamab en tislelizumab in de sluis geplaatst
nov 2023 | Lymfoom, Maag-darm-leveroncologie